Raymond James Financial Services Advisors Inc. grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 14.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,036 shares of the company’s stock after purchasing an additional 1,624 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Apellis Pharmaceuticals were worth $1,188,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of APLS. Clearstead Advisors LLC bought a new stake in shares of Apellis Pharmaceuticals during the first quarter worth $27,000. IFP Advisors Inc increased its position in shares of Apellis Pharmaceuticals by 49,525.0% during the first quarter. IFP Advisors Inc now owns 1,985 shares of the company’s stock worth $39,000 after acquiring an additional 1,981 shares in the last quarter. US Bancorp DE increased its position in shares of Apellis Pharmaceuticals by 391.2% during the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after acquiring an additional 884 shares in the last quarter. Parallel Advisors LLC increased its position in shares of Apellis Pharmaceuticals by 1,173.0% during the first quarter. Parallel Advisors LLC now owns 942 shares of the company’s stock worth $62,000 after acquiring an additional 868 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Apellis Pharmaceuticals by 110.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 2,366 shares of the company’s stock worth $156,000 after acquiring an additional 1,243 shares in the last quarter. 90.43% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on APLS shares. Bank of America increased their price objective on shares of Apellis Pharmaceuticals from $44.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, October 12th. HC Wainwright reaffirmed a “buy” rating and issued a $82.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, September 26th. Stifel Nicolaus raised their target price on shares of Apellis Pharmaceuticals from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, August 29th. Wells Fargo & Company raised shares of Apellis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $34.00 to $64.00 in a research report on Friday, September 15th. Finally, JPMorgan Chase & Co. raised shares of Apellis Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $60.00 to $81.00 in a research report on Friday, October 6th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $69.00.
Apellis Pharmaceuticals Stock Performance
NASDAQ APLS opened at $48.45 on Friday. The firm has a 50-day moving average of $42.63 and a 200-day moving average of $62.21. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.52 and a current ratio of 5.11. The stock has a market cap of $5.70 billion, a PE ratio of -8.31 and a beta of 1.10. Apellis Pharmaceuticals, Inc. has a 52-week low of $19.83 and a 52-week high of $94.75.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last posted its earnings results on Monday, July 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.33. Apellis Pharmaceuticals had a negative net margin of 356.02% and a negative return on equity of 212.82%. The company had revenue of $95.00 million during the quarter, compared to analysts’ expectations of $70.38 million. During the same quarter last year, the company posted ($1.46) EPS. Apellis Pharmaceuticals’s quarterly revenue was up 482.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -4.35 EPS for the current year.
Insiders Place Their Bets
In other Apellis Pharmaceuticals news, Director Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $45.34, for a total value of $56,675.00. Following the completion of the sale, the director now owns 367,420 shares in the company, valued at approximately $16,658,822.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Apellis Pharmaceuticals news, Director Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $45.34, for a total value of $56,675.00. Following the completion of the sale, the director now owns 367,420 shares in the company, valued at approximately $16,658,822.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Cedric Francois sold 150,000 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $41.75, for a total transaction of $6,262,500.00. Following the completion of the sale, the chief executive officer now owns 424,655 shares of the company’s stock, valued at approximately $17,729,346.25. The disclosure for this sale can be found here. Insiders sold 210,914 shares of company stock worth $8,654,691 in the last quarter. 7.50% of the stock is currently owned by corporate insiders.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).
Recommended Stories
- Five stocks we like better than Apellis Pharmaceuticals
- 3 REITs to Buy and Hold for the Long Term
- Watch for bears as S&P 500 slices 200-day line
- Quiet Period Expirations Explained
- Reasons UPS is a strong sell: Reasons to buy it when it bottoms
- How Can Investors Benefit From After-Hours Trading
- 3 hot mid-caps set to report Q3 earnings
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
